Literature DB >> 14729764

Tissue kinetics of telithromycin, the first ketolide antibacterial.

C Muller-Serieys1, J Andrews, F Vacheron, C Cantalloube.   

Abstract

The potential efficacy of an antibacterial depends not only on its spectrum of activity but also on its concentration at the site of infection. The tissue kinetics of telithromycin-the first ketolide antibacterial-are reviewed here. Telithromycin accumulates rapidly in white blood cells, inflammatory fluid, and cells and tissues of the upper and lower respiratory tract, with mean concentrations above the MICs of key respiratory pathogens. Tissue kinetics of telithromycin support facilitated delivery to the site of infection, good efficacy against intracellular respiratory pathogens and respiratory pathogens at extracellular sites in the airways, and effectiveness in the treatment of upper and lower respiratory tract infections (RTIs). The tissue kinetics profile of telithromycin, together with its microbiological profile, makes it a promising new antibacterial for the treatment of community-acquired RTIs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729764     DOI: 10.1093/jac/dkh068

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Ketolides in the treatment of community-acquired respiratory tract infections: A review.

Authors:  Martin S Lipsky
Journal:  Curr Ther Res Clin Exp       Date:  2005-05

2.  Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.

Authors:  George G Zhanel; Christel Johanson; Nancy Laing; Tamiko Hisanaga; Aleksandra Wierzbowski; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin.

Authors:  Martina Bosnar; Zeljko Kelnerić; Vesna Munić; Vesna Eraković; Michael J Parnham
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 4.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

Authors:  Steven D Brown
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia.

Authors:  George G Zhanel; Tamiko Hisanaga; Aleksandra Wierzbowski; Daryl J Hoban
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

8.  In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations.

Authors:  Elena De Vecchi; Lucia Nicola; Monica Larosa; Lorenzo Drago
Journal:  BMC Microbiol       Date:  2008-01-29       Impact factor: 3.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.